Canaccord Genuity Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $992
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst John Newman has upgraded Regeneron Pharmaceuticals from Hold to Buy and raised the price target from $720 to $992.
August 21, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals has been upgraded from Hold to Buy by Canaccord Genuity, with a raised price target from $720 to $992.
The upgrade from Hold to Buy indicates a positive outlook for Regeneron Pharmaceuticals. The raised price target from $720 to $992 suggests that the analyst expects the stock to perform well in the future. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100